Chardan Capital Markets Downgrades ARIAD Pharmaceuticals (ARIA) to Neutral
Tweet Send to a Friend
Chardan Capital Markets downgraded ARIAD Pharmaceuticals (NASDAQ: ARIA) from Buy to Neutral following Q4 results as shares approached their $9 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE